Details of the Drug Combinations

General Information of This Drug (ID: DMSHPW8)

Drug Name

Tolterodine DMSHPW8

Synonyms

Tolterodina; Tolterodinum; Detrol (TN); Detrusitol (TN); Kabi-2234; 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol; 2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol; 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol

Indication

Disease Entry	ICD 11	Status	REF
Overactive bladder	GC50.0	Approved	[1]
Priapism	N.A.	Investigative	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antispasmodics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Tamsulosin + Tolterodine	DCE81VD	Tamsulosin	Prostatitis	[3]
Tolterodine + Clonazepam	DC2XDAZ	Clonazepam	Pain	[4]
Amitriptyline + Tolterodine	DC9G6AT	Amitriptyline	Chronic Pain	[5]
Mirabegron + Tolterodine	DCYUXNZ	Mirabegron	Overactive Bladder (OAB)	[6]
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Tolterodine FDA Label
3	ClinicalTrials.gov (NCT00913315) Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis
4	ClinicalTrials.gov (NCT01011036) Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers
5	ClinicalTrials.gov (NCT02256943) Genetic Determinants of Amitriptyline Efficiency for Pain Treatment
6	ClinicalTrials.gov (NCT02294396) Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.